Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Telotristat Etiprate in Hepatic Impairment
NCT02683577Phase 1Completed
- Sponsor
- Ipsen
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Ipsen. Primary endpoints: Maximum Observed Plasma Drug Concentration at Day 4, Time to Maximum Observed Plasma Concentration at Day 4 and 4 more. Started Feb 2016; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT02683577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683577.